|
|
|
|
|
|
Role of 5' mRNA and 5' U snRNA cap structures in regulation of gene expression |
People involved:
Collaboration with (in Department of Biophysics):
Further collaboration:
|
Keywords:
5' mRNA cap, (monometyloguanozyno kap; m7GpppG; MMG kap) Eukariotic Initiation Factor 4E (eIF4E) Cap Binding Complex (CBC) m32,2,7GpppN (trimetylguanozyno kap; TMG kap) U snRNA (małe j±drowe RNA) Translacja Splicing Research interests:
MMG cap in mRNA plays an essential role in initiation of protein translation. It is recognized by eukaryotic protein factor eIF4E, which enables creation of initiation translation complex consisting of mRNA, a number of additional protein factors and a small ribosomal subunit 40S (see Scheme). MMG cap stimulates also splicing of pre-mRNA, and, to some extent, export of MMG-capped RNAs from the nucleus into the cytoplasm.
Laboratory of Gene Expression deals with synthesis of both natural as well as chemically modified cap analogues and their broad use in biochemical and biophysical research into molecular mechanisms of gene regulation. Specifically introduced chemical modifications on nucleic bases, ribofuranose rings and phosphate chain, provided over one hundred model cap analogues, many of which compete with mRNA for binding site in eIF4E thus inhibiting protein translation. Research into inhibition of protein translation by cap analogues enabled to define a number of structural cap parameters responsible for binding to eIF4E (f.e. see 1-3,11). We were the first to obtain synthetically TMG cap (m32,2,7GpppN) and its analogues (3), which were crucial to the discovery of signalling role of TMG cap in nuclear import of some U snRNAs (4,5), and to the discovery and initial characterisation of five eIF4E isoforms from nematode C.elegans (10,15,16).
Another application of MMG cap analogues and affinity resins based on them allowed to identify nuclear cap binding complex (CBC) and to prove its stimulating effect on pre-mRNA splicing (6,7). Currently, together with Professor Stolarski's team we are conducting research into interactions of eIF4E isoforms from C.elegans and CBC with model cap analogues. It is aimed to identify binding sites of specific protein factors to the cap structures.
Recently we have synthesized ARCAs: Anti Reverse Cap Analogues - dinucleotide cap analogues with chemically blocked 3' hydroxyl group in 7-methylguanosine (f.e. m73'OMeGpppG) (13). These analogues, thanks to their exclusively correct incorporation into RNA chain (in in vitro transcription of a DNA template using a bacteriophage RNA polymerase in the presence of ribonucleoside triphosphates and dinucleotide cap analogue), have found broad application in preparation of synthetic RNA transcripts. mRNAs capped with ARCA proved to be twofold more effective templates in protein synthesis compared to their counterparts capped with traditional m7GpppG cap (13).
Our laboratory is also involved in obtaining the protein factors (wild type and mutants) essential to biophysical research into their interactions with cap structures (see f.e. 18).
The currently conducted projects involve: (a) chemical synthesis of oligonucleotides capped with natural and modified cap dinucleotides, (b) developing the efficient methodology of capping oligos on solid support, (c) synthesis of cap dinucleotides resistant to degradation by pyrophosphatases, (d) synthesis of new ARCAs with higher translational activity, (e) synthesis of new inhibitors of translation based on cap analogues that are able to cross the plasma membrane, in an attempt to target cap-dependent translation as an anticancer strategy, (f) investigation the role of eIF4E phosphorylation, (g) biophysical studies of cap analogs interactions with cap binding proteins (within close collaboration of Prof. R. Stolarski and Prof. J. Antosiewicz).
|
Selected publications:
Supported by:
|